Author Archives: webmaster

Cell Therapies P/L joins CRC for Cell Therapy Manufacturing (CRC-CTM)

April 3rd, 2013 | Posted by webmaster in News - (Comments Off on Cell Therapies P/L joins CRC for Cell Therapy Manufacturing (CRC-CTM))

Cell Therapies P/L has become an essential partner in the recently approved Cooperative Research Center for Cell Therapies Manufacturing (CRC-CTM). The combination of world leading academic researchers with local and overseas commercial companies is a novel feature of the Australian Government sponsored CRC program.

The CRC-CTM’s research is directed towards improved manufacturing capabilities and lowered cost of goods (COGS). Targeted clinical indications include unresolved diabetic foot ulcers, Graft vs Host disease (GvHD) for transplant patients, type 2 diabetes and diseases of the immune system where T-cells are involved.

Cell Therapies P/L will provide the regulatory compliant environment that facilitates the migration of CRC-CTM research into the clinic. A feature of this CRC is the seamless integration of pure research with commercial scale reduction to practice via first in man and subsequent routine treatments.

New Chairman Appointed by Cell Therapies

January 28th, 2013 | Posted by webmaster in News - (Comments Off on New Chairman Appointed by Cell Therapies)

Cell Therapies Pty Ltd is pleased to announce that Dr Christian Behrenbruch has been appointed as Chairman of the Melbourne-based life sciences company. Dr Behrenbruch will also serve as a nominee non-executive director on behalf of the Peter MacCallum Cancer Centre, the major shareholder of Cell Therapies.

Dr Behrenbruch has a demonstrated track record of building successful organisations in the life sciences and healthcare arena. He is currently the Chief Executive Officer of ImaginAb, Inc. a venture-backed biotechnology company based in California and Singapore. Previous executive roles have included Managing Partner at Momentum Biosciences, Vice President at Siemens Healthcare, Sr. VP at CTI Molecular Imaging (sold to Siemens in a $1.1Bn transaction in 2005) and CEO of Mirada Solutions, a successful UK-based radiology company that was spun-out of the University of Oxford.

Dr Behrenbruch completed his undergraduate studies at Monash University, received a D.Phil (Ph.D) in biomedical engineering from Oxford University and an MBA jointly awarded by New York University and the London School of Economics. Dr Behrenbruch has also held several academic appointments, including a faculty position in the Department of Medical and Molecular Pharmacology at the University of California, Los Angeles. He is currently an adjunct professor and member of the Industry Advisory Board at RMIT University’s College of Business (Melbourne).

“We’re delighted with this appointment as Dr Behrenbruch brings a strong combination of academic excellence in healthcare, understanding of the regulatory challenges of product development and a proven track record as a ‘serial entrepreneur’ in financing and nurturing early-stage companies,” said Ray Wood, CEO of Cell Therapies.

“Cell Therapies has done a remarkable job of building a unique life sciences company with an unmatched track record in manufacturing and deploying complex products in the cell therapies space,” commented Dr. Behrenbruch. “The company has exciting growth potential in terms of new products and regional market opportunities as this ‘pillar’ of healthcare starts to yield technologies with significant therapeutic potential.”

For more information, contact Ray Wood at Cell Therapies on: 61 3 9656 1615 or raywood@celltherapies.com.au / www.celltherapies.com.au

Cell Therapies Gains Access to Innovative Cartilage Product

January 28th, 2013 | Posted by webmaster in News - (Comments Off on Cell Therapies Gains Access to Innovative Cartilage Product)

Cell Therapies has announced an exclusive licensing agreement with South Korean-based Medipost for the distribution and manufacture of its innovative product Cartistem® a cellular treatment for osteoarthritis (OA) and focal defects of the knee

CARTISTEM® is the world’s first therapeutic agent approved for treating degenerative arthritis and knee cartilage defects, which is based on stem cells derived from cord blood.

“CARTISTEM® is a treatment for an indication with an increasing frequency due to an aging population,” said Mr Ray Wood, CEO of Cell Therapies. “We believe this novel allogenic cell therapy can deliver relief to patients without an alternative.”

Since completion of Phase III trials and regulatory approval in Korea more than 450 patients have been successfully treated. A key finding of the Phase III trial was the positive outcome for older patients who have previously not been considered suitable for treatment.

For more information, contact Ray Wood at Cell Therapies on: 61 3 9656 1615 or via raywood@celltherapies.com.au

NEWLY DEVELOPED NANOPARTICLES FOR CELL TRACKING

January 29th, 2010 | Posted by webmaster in Research - (Comments Off on NEWLY DEVELOPED NANOPARTICLES FOR CELL TRACKING)

Giovanni Mandarano, Jyoti Arora, Dominic Wall, Simon Harrison, Noelene Bergen, Dodie Pouniotis and Peter Eu

The utilisation of magnetic resonance imaging (MRI) to noninvasively monitor cells using superparamagnetic iron oxide nanoparticles (SPIONs) as MRI contrast agents has been one of the major research focuses over the past several years. The ability to use MRI to image longitudinally offers an invaluable opportunity to track the migration, persistence and distribution of cell based therapeutics in vivo in humans.

Current approaches for cell labelling have focused on using commercial SPIONs with varying success. Therefore, there is a clinical need to develop SPIONs that are non-toxic, with appropriate size and high MRI contrast. We have utilised SPIONs with a silica coating to investigate the labelling ability and contrast enhancement of CD45+ and CD34+ expressing cells.

For more details, click here.